We are pleased to share that the recruitment for part one of the LIVEDIFF Phase 1/2 trial is closed!

LIVEDIFF aims to demonstrate EXL01's safety and efficacy in patients with high-risk of Clostridioides difficile infection (CDI). The trial is supported by the French Ministry of Health and conducted in collaboration with Dr Nicolas Benech at Hospices Civils de Lyon - HCL.

With over 120,000 cases and nearly 3,700 deaths yearly in Europe alone, CDI poses a significant healthcare challenge.

We are thankful to all patients who are participating in this study and helping us in bringing new therapeutic options for CDI.

This marks an important milestone in our journey to demonstrate the proof of concept of our groundbreaking drug candidate EXL01 in several therapeutic areas.

Stay tuned for more updates on this exciting trial!